STOCK TITAN

Virexit Technologies, Inc. Secures Direct U.S. Rights to Distribute Airros(TM) Sanitation System

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

VirExit Technologies (OTC:VXIT) has secured a direct national reseller agreement with SAGE Industrial Corporation to distribute AirROS's patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States. The company projects revenue of $196,721 in 2H 2025, scaling to $786,885 in FY2026 and $1.57M in FY2027.

The business model combines high-margin hardware sales with recurring subscription revenue from filter replacements, remote monitoring, and maintenance. Recurring service revenues are expected to represent 30.5% of total sales, maintaining a 53% blended gross margin with an 18-month payback period. The company plans to launch AirROS Home for residential consumers in Q4 2025, targeting the $2.1B U.S. residential air-purifier market.

Initial deployment includes 5 pilot sites in 2H-FY25, expanding to 20 deployments in FY26 and 40 in FY27, focusing on major metropolitan markets across various sectors including offices, schools, and healthcare facilities.

Loading...
Loading translation...

Positive

  • Projected strong revenue growth from $196K to $1.57M in 2 years
  • High blended gross margin of 53% with 35% operational profit
  • Recurring revenue model with 30.5% of sales from service contracts
  • Lab-validated technology with 99.99% pathogen reduction in 30 minutes
  • 18-month payback period per installation
  • Expansion into residential market in Q4 2025 opens access to 128M U.S. households

Negative

  • Initial revenue projections are relatively modest ($196K in 2H 2025)
  • Positive cash flow not expected until mid-2026
  • Limited initial deployment of only 5 pilot sites in 2H-FY25
  • Dependent on successful pilot program results for expansion

News Market Reaction 1 Alert

-22.22% News Effect

On the day this news was published, VXIT declined 22.22%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows - POISED TO DRIVE 35% OPERATIONAL PROFIT

NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 / VirExit Technologies, Inc. (OTC PINK:VXIT) ("VirExit" or the "Company"), a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE"). This agreement establishes VirExit as the U.S. distributor of AirROS's patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027.

Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 - 30.5% of total AirROS sales, scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.

3 Year Revenue Forecast

FY Period

Total Revenue

Service & Maint Gross Margin (%) / year

Hardware Units Gross Margin (%)

Blended Gross Margin (%)

SG&A (% of Rev)

Operational Profit (%)

2H FY25 (5 Pilot Programs)

$196,721

51.8%

55%

53.0%

18.0%

35%

FY26 (20 Unit Installs)

$786,885

51.8%

55%

53.0%

18.0%

35%

FY27 (40 Unit Installs)

$1,573,770

51.8%

55%

53.0%

18.0%

35%

*Deployment Ramp - 2H-FY 25': 5 pilot sites; FY 26': 20 deployments; FY 27': 40 deployments; All located in major metropolitan markets to maximize visibility and service efficiency; Sales, installation and support teams staged in target metros. Lab-testing and HVAC partners engaged locally to maintain margins.

Disruptive Technology Meets Rapid Market Expansion
AirROS's proprietary ROS technology continuously neutralizes viruses, bacteria, molds and odors-without chemical residues-earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening IAQ mandates in schools, healthcare and hospitality, VirExit's nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.

"By combining SAGE's breakthrough ROS platform with VirExit's proven go-to-market engine, we're not only enhancing safety but unlocking a durable, subscription-driven growth engine," said James Katzaroff, CEO of VirExit Technologies. "Investors should expect steady quarterly revenue inflections, robust margin expansion and a clear pathway to positive cash flow by mid-2026."

"VirExit's market reach and ESG-aligned vision make them the ideal partner to scale AirROS," added Brian Taylor, CEO of SAGE Industrial. "Together, we'll set a new industry benchmark in continuous, on-site sanitation."

Consumer Market Expansion & Public Health Impact
To complement our B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).

  • Mold & Indoor Allergens

    • Current State: Roughly 50 % of U.S. homes contend with visible mold or dampness; up to 20 % of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).

    • AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99 %, reducing allergy flare-ups and related healthcare costs.

  • Childhood Asthma & Seasonal Pathogens

    • Current State: Asthma affects 1 in 13 Americans (≈ 25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.

    • AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40 %, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.

  • Elderly & Immunocompromised Households

    • Current State: As immune defenses wane with age, older adults (12 % of the U.S. population) face higher rates of respiratory infections and hospital admissions-burdening families and the healthcare system.

    • AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.

By bridging our enterprise and consumer offerings, VirExit not only multiplies its addressable market-but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.

Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals-Office Buildings (US $1.2 B market, delivering 10-20% HVAC savings and 35% fewer sick-days), Schools & Universities (US $0.7 B market, driving a 30% drop in absenteeism), and Long-Term Care (US $1.0 B market, achieving 40% fewer hospital-acquired infections).

After validating these results, VirExit will extend into 15 major metro areas-rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2-7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS's upfront investment-recouped through energy savings, reduced maintenance, and fewer sick-day losses-pays for itself in under 18 months, delivering a full return within a year and a half. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.

Vertical

Current Pain Point / Infrastructure Gap

US Market (2024)

Global Market (2024)

Cost-Saving & Revenue Benefits

Occupant Benefits

Office Buildings

"Sick building syndrome"• High HVAC energy spend

$1.2 B

$3.4 B

10-20% lower HVAC costs• 35% fewer sick-days (~$300/emp./yr)

+15% cognitive performance• Reduced absenteeism• Higher employee morale

Hotels & Restaurants

Odor/stale-air complaints• Heavy chemical cleaning

$0.9 B

$2.6 B

+5% occupancy lift• +10% F&B revenue• Lower chemical spend

Enhanced guest comfort• Fewer negative reviews• Higher return visits

Schools & Universities

Aging HVAC• High absenteeism

$0.7 B

$1.8 B

30% drop in absenteeism (>$400/student/yr)• Reduced HVAC maintenance

Improved attention & test scores• Safer learning environment

Long-Term Care

Poor infection control• Regulatory compliance risk

$1.0 B

$2.8 B

40% fewer HAIs• Avoidance of fines/penalties

Better resident health & comfort• Lower staff turnover

Retail

Uneven air quality• Low shopper dwell time

$0.8 B

$2.1 B

+15% dwell time → +5% sales lift• Reduced shrinkage

More enjoyable shopping• Increased customer loyalty

Commercial & Government

Outdated HVAC• Costly retrofits• Compliance mandates

$1.0 B

$3.0 B

Avoid $1 M+ in retrofit costs• Demonstrated regulatory compliance

Higher employee productivity• Enhanced public trust

Apartment Complexes

Poorly ventilated common areas• High tenant turnover

$0.6 B

$1.6 B

10% reduction in churn• Fewer maintenance tickets

Healthier living spaces• Higher tenant satisfaction

Cannabis Cultivation

Mold & humidity control• Crop-loss risk

$0.2 B

$0.5 B

+15% yield increase• -20% pathogen-related loss

Safer work environment• Regulatory peace of mind

Grocery Stores

Rapid spoilage• Contamination risk

$0.5 B

$1.3 B

+7-14 day shelf-life → -3% waste• Higher produce margins

Greater consumer confidence• Better food safety

Fitness Facilities

Poor airflow in gyms/studios• Member health complaints

$0.4 B

$1.0 B

-15% membership churn• Lower cleaning & HVAC costs

Healthier workouts• Reduced risk of airborne illness

Daycare Centers

Frequent outbreaks → closures

$0.2 B

$0.5 B

-50% outbreak events• Avoided closure & liability costs

Safer child-care environment• Peace of mind for parents

Pro Sports Arenas

High transmission risk in crowds

$0.15 B

$0.4 B

+10% ticket renewals• Lower staff sick-leave payouts

Safer fan experience• Reduced player/staff illness

Forward-Looking Statements
This release contains forward-looking statements regarding our expectations for future performance. Actual results may differ materially. See the Company's filings with OTC Markets for a full discussion of risk factors and safe-harbor provisions.

About VirExit Technologies, Inc.
VirExit Technologies, Inc. is a U.S. reseller and marketer of AirROS™-a patented reactive oxygen species (ROS) air-and-surface sanitation platform proven in independent labs to reduce pathogens by 99.99% within 30 minutes. AirROS™ solutions are offered through recurring-revenue service agreements for healthcare, senior living, commercial real estate, hospitality, education, and residential customers. For more information, visit virexittechnologies.com.

Address:
1280 Lexington Avenue
FRNT2 #1292
New York, NY 10028

Please feel free to contact us or follow us on Twitter / X, to learn more.

Contact:
VirExit Technologies, Inc.
James C Katzaroff, CEO
Phone: +1 509-531-1671
jim@katzaroff.com

Investor Relations:
Email: ir@virexittechnologies.com

Website:
Visit: www.virexittechnologies.com

SOURCE: VirExit Technologies, Inc.



View the original press release on ACCESS Newswire

FAQ

What is VirExit Technologies' (VXIT) projected revenue for FY2027?

VirExit Technologies projects revenue of $1,572,770 for fiscal year 2027, with a blended gross margin of 53% and operational profit of 35%.

What percentage of VXIT's AirROS sales will come from recurring service revenue?

Recurring service revenue is projected to represent 30.5% of total AirROS sales, starting at $60,000 in 2H FY2025 and scaling to $480,000 by FY2027.

When will VirExit Technologies launch AirROS Home for residential consumers?

VirExit plans to launch AirROS Home for residential consumers in Q4 2025, targeting the $2.1 billion U.S. residential air-purifier market.

What is the effectiveness rate of VirExit's AirROS technology for pathogen reduction?

AirROS technology has been independently lab-validated to achieve up to 99.99% pathogen reduction within 30 minutes.

What is the payback period for VirExit's AirROS system installations?

The projected payback period for AirROS system installations is under 18 months per installation.
Virexit Technologies Inc

OTC:VXIT

VXIT Rankings

VXIT Latest News

VXIT Stock Data

1.43M
3.56B
Utilities - Renewable
Utilities
Link
United States
Richland